-
BROWSE TOPICS IN CLINICAL MANAGEMENT:
Antiretroviral Therapy- Complications of HIV/HAART
- Research & Development
- Clinical Trials
- Quality of Life & Patient Care
Antiretroviral Therapy
Tenofovir (Viread): Research
HIV Treatment Research
- Clinical Trials Using Tenofovir (Regularly Updated)
U.S. and international trials currently recruiting.
From U.S. National Institutes of Health - Literature Citations for Tenofovir (Regularly Updated)
From U.S. National Institutes of Health - More Patients With High Viral Loads Experience Virologic Failure When Starting Therapy With an Abacavir-Based Regimen Than a Tenofovir-Based Regimen (August 7, 2008)
An interview with Paul Sax, M.D.
From The Body PRO - Combining Sustiva + Viread May Increase Liver Risk, Case Reports Suggest (May 9, 2008)
In aidsmap.com - NIAID Study Finds Red Flags When Using Abacavir/Lamivudine as First-Line Therapy in Patients With High Viral Load (February 28, 2008)
Combination therapy that includes ABC/3TC found less effective in subgroup of antiretroviral-naive individuals.
From U.S. National Institute of Allergy and Infectious Diseases - Tenofovir Appears Effective Against HIV and Hepatitis B in Coinfected People (June 12, 2007)
From aidsmap.com - Once-Daily Lamivudine + Nevirapine + Tenofovir Leads to High Failure Rates in Treatment-Naive Individuals (March 8, 2007)
In aidsmap.com - Link Between Tenofovir and Renal Toxicity Remains Tenuous, but Monitoring Is Warranted (February 8, 2006)
In The 13th Conference on Retroviruses and Opportunistic Infections - HIV JournalView: Risk of Tenofovir Nephrotoxicity May Be Real, Though Murky (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO - HIV JournalView: Tenofovir + Didanosine: The Downfall of a Lovely Combination (January 2006)
Part of David Wohl, M.D.'s review of the top 10 HIV research reports of 2005.
In HIV JournalView, from The Body PRO - Researchers Uncover Possible Alternative Pathway to Tenofovir Resistance (December 17, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Spanish Study Finds Association Between Long-Term Treatment With Tenofovir and Kidney Toxicity Still Unclear (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Switching Due to Lipoatrophy: Tenofovir Bests Abacavir in Tolerability, Lipid Profile (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Tenofovir Proves Safe for Kidneys After Three Years of Use (December 16, 2005)
In The 45th Interscience Conference on Antimicrobial Agents and Chemotherapy - Quad Nucleoside/tide Regimen of Trizivir + Tenofovir Effective, Well Tolerated as Second-Line Therapy (July 27, 2005)
In The 3rd International AIDS Society Conference on HIV Pathogenesis and Treatment - Once-Daily Abacavir + Lamivudine + Tenofovir Fails in Naive Patients (April 2005)
In Expert Opinion on Investigational Drugs, from The Body PRO - Sequencing and 2 of the Most Popular Backbone Regimens (February 25, 2005)
A comparison of resistance mutations with abacavir + lamivudine versus tenofovir + lamivudine.
In The 12th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Tenofovir and Efavirenz Show Promise as Two-Drug Maintenance Regimen (July 26, 2004)
The so-called "COOL Study" examined this novel two-drug regimen in patients who had already achieved viral suppression on traditional, three-drug HAART.
From aidsmap.com - Substituting With Tenofovir Decreases the Adverse Effects Seen With Other NRTIs (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO - Update on Long-Term Follow-Up Studies on Tenofovir (July 14, 2004)
In The XV International AIDS Conference, from The Body PRO - Failure of Tenofovir/Abacavir/Lamivudine Combination Still Unexplained (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO - Lamivudine/Abacavir Is an Effective Nucleoside Backbone in Combinations Other Than With Tenofovir (July 13, 2004)
Results suggest that the K65R mutation is behind the failure of this three-drug combination.
In The XV International AIDS Conference, from The Body PRO - Tenofovir and Abacavir Do Not Interact in Patients on Triple-Nucleoside Regimens (July 13, 2004)
In The XV International AIDS Conference, from The Body PRO - Both Tenofovir and Stavudine Well Tolerated in HCV-Coinfected Patients (July 12, 2004)
In The XV International AIDS Conference, from The Body PRO - High Rate of Virologic Failure With Once-Daily ddI/3TC/TDF (November 2003)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Further Case Report of Lactic Acidosis Linked to Tenofovir/ddI (September 29, 2003)
From aidsmap.com - A Look at Tenofovir Drug-Drug Interactions (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Interim Analysis of Failure of Tenofovir/Abacavir/3TC Regimen (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - No PK Interaction Seen Between FTC and AZT or Tenofovir (September 16, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Dyslipidemia: Change to Tenofovir? (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - No Major Renal Problems With Tenofovir Were Identified in the Naive Population Evaluated in the GS 903 Study (September 15, 2003)
In The 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy, from The Body PRO - Viread, Epivir and Ziagen Combination -- Failure in Naive Patients With a Once-Daily Regimen (September/October 2003)
Daniel S. Berger, M.D., chief investigator in study ESS30009, examines what went wrong.
To read PDF, click here
In Positively Aware, from Test Positive Aware Network - Early Virologic Non-Response in Patients With HIV Infection Treated With Lamivudine, Abacavir and Tenofovir (July 25, 2003)
"Dear Healthcare Provider" letter from GlaxoSmithKline.
From U.S. Food and Drug Administration - Abacavir/3TC/Tenofovir Combination Fails in Treatment-Naive Patients (July 14, 2003)
Analysis by Benjamin Young, M.D., Ph.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Abacavir/3TC/Tenofovir Combination Failure in Treatment-Naive Patients (July 14, 2003)
Analysis by Timothy Wilkin, M.D.
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - For Potency Tenofovir Equals d4T but Tenofovir Beats d4T With Less Frequent and Common Side Effects (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Is Trizivir Plus Tenofovir Effective in Patients With Possible or Proven Reverse Transcriptase Resistance? (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - More Results Reported on Study 903: Tenofovir + 3TC + Efavirenz Vs. d4T + 3TC + Efavirenz (July 14, 2003)
In The 2nd International AIDS Society Conference on HIV Pathogenesis and Treatment, from The Body PRO - Tenofovir Side Effects (April 13, 2003)
Report from the 12th Annual Canadian Conference on HIV/AIDS Research, April 10-13, 2003.
From Canadian AIDS Treatment Information Exchange - HIV-Positive Man Dies of Kidney Failure and Lactic Acidosis Due to Tenofovir/ddI Interaction (April 8, 2003)
From aidsmap.com - More Regarding Tenofovir Versus d4T in Treatment-Naive Subjects (February 14, 2003)
Newly released data on bone-related side effects for some tenofovir users.
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Didanosine and Tenofovir DF Drug-Drug Interaction: Assessment of Didanosine Dose Reduction (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Lack of Interaction Between Stavudine Extended-Release Formulation and Tenofovir Disoproxil Fumarate (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Pharmacokinetic Parameters of Atazanavir/Ritonavir When Combined to Tenofovir in HIV Infected Patients With Multiple Treatment Failures: A Substudy of Puzzle2-ANRS 107 Trial (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Tenofovir Disoproxil Fumarate and Lamivudine Combination Therapy Compared to Lamivudine Alone for HBV in Therapy-Naive HIV/HBV Co-Infected Patients: 48-Week Interim Results (February 12, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Efficacy and Safety of Tenofovir DF Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in Antiretroviral-Naive Patients: 96-Week Preliminary Interim Results (February 11, 2003)
In The 10th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - Research From the 42nd ICAAC: A Nucleoside (FTC) and a Nucleotide (Tenofovir) Outdo d4T (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Research From the 42nd ICAAC: Tenofovir Intensification Allies: Low Load, No TAMs, M184V (December 2002)
In IAPAC Monthly, from International Association of Physicians in AIDS Care - Comparison of the Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy After 48 Weeks of Treatment (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Genotypic and Phenotypic Characterization of Virologic Failure Through 48 Weeks Among Treatment-Naive Patients Taking Tenofovir DF or Stavudine in Combination With Lamivudine and Efavirenz (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Pharmacokinetics Following Single Doses Administrations of Tenofovir DF in Subjects With Renal Impairment (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Safety Profile of Tenofovir DF in Treatment-Experienced Patients From Randomized, Placebo-Controlled Clinical Trials (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - The Development of K65R Versus Thymidine Analogue-Associated Mutations in Antiviral-Treated Patients (November 21, 2002)
In The 6th International Congress on Drug Therapy in HIV Infection, from The Body PRO - Successful Switch From Stavudine to Once-Daily Tenofovir Based Regimen in Patients With Fully Suppressed HIV (October 26, 2002)
In 40th Annual Meeting of the Infectious Diseases Society of America, from The Body PRO - Viread-Videx EC Drug Interactions -- What's a Person to Do? (Fall 2002)
To read PDF, click here
In STEP Perspective, from Seattle Treatment Education Project - Efficacy and Safety of Tenofovir Disoproxil Fumarate Versus Stavudine When Used in Combination With Lamivudine and Efavirenz in HIV-1 Infected Patients Naive to Antiretroviral Therapy: 48-Week Interim Results (July 12, 2002)
In The XIV International AIDS Conference, from The Body PRO - Expanded Response Analyses of Tenofovir DF Therapy by Baseline Resistance Genotype and Phenotype (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO - Tenofovir DF and Didanosine EC: Investigation of Pharmacokinetic Drug-Drug and Drug-Food Interactions (July 11, 2002)
In The XIV International AIDS Conference, from The Body PRO - Tenofovir DF: A 48-Week Final Analysis From a Phase III Randomized, Double Blind, Placebo Controlled Study in Antiretroviral Treatment-Experienced Patients (July 10, 2002)
In The XIV International AIDS Conference, from The Body PRO - Efficacy of Tenofovir DF Monotherapy in Chronically HIV-1 Infected Antiretroviral Treatment-Naive Patients (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Safety Profile of Tenofovir DF in Antiretroviral Treatment-Experienced Patients From Randomized, Double-Blind, Placebo-Controlled Clinical Trials (July 9, 2002)
In The XIV International AIDS Conference, from The Body PRO - Retrospective Analysis of the Use of Tenofovir DF in a Private Practice (July 8, 2002)
In The XIV International AIDS Conference, from The Body PRO - Determining the Relative Efficacy of Tenofovir DF Using Frequent Measurements of HIV-1 RNA During a Short Course of Monotherapy in Antiretroviral Drug Naive Individuals (February 25, 2002)
In The 9th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - More Uses for Tenofovir? (January 25, 2002)
The drug's usefulness in pregnant women, as a microbicide or as first-line therapy has yet to be thoroughly investigated.
To read PDF, click here
In AIDS Treatment News, from AIDS Treatment News - Tenofovir DF: A 24-Week Interim Analysis From a Phase III Double-Blind, Placebo-Controlled Study in Antiretroviral-Experienced Patients (December 17, 2001)
In 41st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC 2001), from The Body PRO - Tenofovir DF 907 Study: Tenofovir as Intensification Agent (October 30, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Lack of Clinically Relevant Drug-Drug Interactions Between Tenofovir DF and Efavirenz, Indinavir, Lamivudine and Lopinavir/Ritonavir in Healthy Subjects (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Tenofovir DF 300 mg Consistently Demonstrates Anti-HIV Activity Regardless of Baseline Demographic Characteristics in Antiretroviral Experienced HIV-1-Infected Patients (October 29, 2001)
In 8th European Conference on Clinical Aspects and Treatment of HIV-Infection, from The Body PRO - Phase I/II Trial of the Pharmacokinetics, Safety, and Antiretroviral Activity of Tenofovir Disoproxil Fumarate in HIV-Infected Adults (October 2001)
From Antimicrobial Agents and Chemotherapy - Report on FDA Antiviral Advisory Committee Discussion of Viread (October 2001)
Including descriptions of Gilead's clinical trials for the drug.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Tenacious Tenofovir Struts its Stuff in a Virtual ICAAC (October 2001)
Highlights from the abstracts for ICAAC 2001.
In GMHC Treatment Issues, from Gay Men's Health Crisis - Highlights From Retrovirus 2001: Tenofovir DF Study 902 (Spring 2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Low Concentrations of Mycophenolic Acid Augment the Antiretroviral Activity of Abacavir (ABC), Didanosine (ddI), Tenofovir (TFV), and the Combination of ABC and ddI In Vitro (February 6, 2001)
In The 8th Conference on Retroviruses and Opportunistic Infections, from The Body PRO - ICAAC and Lipodystrophy Conference Coverage on Tenofovir (Winter 2000/2001)
In Bulletin of Experimental Treatments for AIDS, from San Francisco AIDS Foundation - Change to Abacavir-Lamivudine-Tenofovir Combination Treatment in Patients With HIV-1 Who Had Complete Virological Suppression
In The Lancet
  |